Two Dubai Residents Charged in Federal Court Over Counterfeit Ozempic Pipeline From China

What Happened

The U.S. Department of Justice has unsealed an indictment against two Indian nationals and Dubai residents — Swapnadip Roy, 33, and Vicky Ramancha, 37 — accusing them of running a transnational scheme to smuggle counterfeit Ozempic from unauthorized manufacturers in China into the United States. The charges were filed under seal in 2025 in the Middle District of Florida and became public Tuesday.

According to court filings, the pair allegedly imported thousands of counterfeit units and sold them to U.S. distributors at discounted prices, bypassing the licensed wholesale distribution system the FDA oversees. The counterfeit material allegedly included fake packaging, package inserts, pen labels and needles — a full kit designed to convince downstream buyers they were purchasing authentic, manufacturer-authorized product.

Each man faces one count of conspiracy to commit smuggling and to defraud the United States, three counts of smuggling, and two counts of selling and holding counterfeit drugs for sale. If convicted on all counts, both face a maximum of 71 years in prison.

Who Is Affected

• Distributors and pharmacy supply chains — the scheme allegedly targeted the wholesale tier, meaning counterfeit pens could ride legitimate-looking logistics deep into the market.
• Patients and consumers — counterfeit injectables carry risks no label can convey: unknown contents, non-sterile filling environments and no quality control.
• Legitimate manufacturers and pharmacies — whose brands and cold chains are exploited by counterfeiters.
• Researchers — the same unauthorized manufacturing-and-smuggling pipeline supplies gray-market peptide and GLP-1 channels worldwide.

Timeline

• 2023 — The FDA seizes counterfeit Ozempic units already in U.S. distribution and warns the public about fake pens.
• After the seizure — the operation allegedly continued: court filings describe a co-conspirator asking whether the FDA's warning would affect a pending order for 60,000 additional units.
• 2025 — a federal grand jury in the Middle District of Florida indicts Roy and Ramancha under seal.
• September 29, 2026 — the indictment is unsealed and the Justice Department announces the charges.

What This Means for Researchers

This case is a textbook anatomy of counterfeit-drug distribution: unauthorized overseas manufacturing, transnational smuggling, counterfeit packaging down to the needle, and discounted offers to domestic distributors. Every step is engineered to defeat a buyer's ability to distinguish real from fake. For anyone sourcing peptides or GLP-1 receptor agonists for research, the lesson is structural — price and packaging are not evidence of authenticity. The only verification that means anything happens at the analytical level.

How to Verify Your Peptides

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

• Research-grade compounds from documented sources in the peptide directory
• Vetted suppliers in the vendor directory

Sources

Regulatory announcements; U.S. District Court filings; industry reports.